Harry J. Buncke to M. Gazi Yaşargil: a historical lesson in cross-specialty microsurgical innovation
Listen to this summary
This historical review seeks to illustrate the impact of Dr. Harry J. Buncke's innovations in microsurgery on the field of neurosurgery, particularly through his collaboration with Dr. M. Gazi Yaşargil. The authors highlight how Buncke's advancements in microsurgical techniques and instrumentation laid the groundwork for neurosurgical procedures, specifically the first superficial temporal artery-to-middle cerebral artery bypass. By examining the exchange of knowledge at the 1966 Vermont Microvascular Surgery Conference, the paper emphasizes the importance of cross-specialty collaboration in advancing surgical practices.
This is one of 33,000+ journals available on OSLR. Try it free for 14 days.
Free 14-day trial. 33,000+ journals. Cancel anytime.

More from Journal of neurosurgery
View all →Jun 5, 2026 · Journal of neurosurgery
Anatomy of the bony canal containing the middle meningeal artery for a vessel-sparing craniotomy in moyamoya disease
Jun 5, 2026 · Journal of neurosurgery
Enhanced Recovery After Surgery in clipping surgery for unruptured cerebral aneurysm: prospective nonrandomized controlled trial
More in Neurological Surgery
View all →Aug 6, 2026 · Lancet (London, England)
[<sup>177</sup>Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial
Aug 5, 2026 · The New England journal of medicine
Syncope
Jul 31, 2026 · Lancet (London, England)
Multivessel coronary artery bypass grafting via small thoracotomy versus sternotomy (MIST): an investigator-initiated, international, open-label, randomised controlled trial
Jul 30, 2026 · Lancet (London, England)
Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial
Jul 30, 2026 · Lancet (London, England)
Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial
Jul 29, 2026 · Lancet (London, England)
Deramiocel heart-derived cellular therapy in advanced Duchenne muscular dystrophy (HOPE-3): a phase 3, randomised, double-blind, placebo-controlled trial
"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."
Dr. Jennifer Thompson
Portland, OR


